Abstract:Background: Phosphate binders are commonly used in tablet form to help patients with hyperphosphatemia limit their absorption of dietary phosphate. These patients frequently have a heavy tablet burden so alternative formulations provide choice and may support adherence. Lanthanum carbonate (LC) is a phosphate binder currently available as a chewable tablet. This study was conducted to support an application for marketing authorization for the oral powder formulation within the European Union. Objective: The goal of this study was to examine the pharmacodynamics, pharmacokinetics, and tolerability of an oral powder formulation of LC compared with the reference chewable tablet formulation. Methods: A Phase I, single-center, randomized, open-label, 2-period, crossover study to assess pharmacodynamic equivalence of the 2 formulations was conducted in healthy adults aged 18 to 55 years receiving a diet standardized for phosphate content. Individuals were randomized to receive a different formulation in each period, taking 10 doses of 1000-mg LC at 3000 mg/d per period with an intervening washout of ≥14 days. The primary pharmacodynamic variable was mean daily excretion of urinary phosphorus over 3 days while receiving LC. Pharmacodynamic equivalence was confirmed if the 90% CI for the difference between formulations in least squares (LS) mean excreted urinary phosphorus was within ±20% of the LS mean value for the tablet formulation. Secondary end points included determination of pharmacokinetic parameters and assessment of tolerability by recording of adverse events. Results: In total, 72 individuals entered the study. They were predominantly men (72.2%), with a mean (SD) age of 31.4 (8.26) years and a BMI of 25.8 (2.45) kg/m(2). The LS mean (SE) excreted urinary phosphorus was 16.8 (0.48) mmol/d during administration of LC tablets (±20% = ±3.35 mmol/d). The corresponding value during administration of LC oral powder was 15.2 (0.48) mmol/d; 90% CI for the difference between formulations was -2.38 to -0.82 mmol/d, confirming pharmacodynamic equivalence. The most common adverse events were gastrointestinal, and no serious adverse events were recorded. Conclusions: In this multiple-dose study, the oral powder and tablet formulations of LC were well tolerated and met the regulatory criteria for pharmacodynamic equivalence in these healthy volunteers. ClinicalTrials.gov identifier: NCT00880750.

Medicine Candidates of Rare Earths Nano-Lanthanum Hydroxide in Preclinical Studie: a Novel Phosphate Binders

Lanthanum Carbonate for the Treatment of Hyperphosphatemia in Ckd 5d: Multicenter, Double Blind, Randomized, Controlled Trial in Mainland China

Lanthanum Carbonate for Treating End Stage Renal Disease Patients with Hyperphosphatemia：a Rapid Assessment

Lanthanum: a safe phosphate binder

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease

Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects

Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?

Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate

Preparation and Characterization of Lanthanum Carbonate Octahydrate for the Treatment of Hyperphosphatemia

Lanthanum Hydroxide and Chronic Kidney Disease Mineral and Bone Disorder: A Rat Model

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study

Systemic Absorption of Oxylanthanum Carbonate is Minimal in Preclinical Models

Additional Reduction in Serum Phosphorus Levels by Pulverized Lanthanum Carbonate Chewable in Hemodialysis Patients

Evaluation of the potential genotoxicity of the phosphate binder lanthanum carbonate

Tolerability, Safety and Efficacy of a Novel Phosphate Binder VS-505 (AP301): a Phase 2 Dose-Escalation and Dose-Ranging Study in Patients Undergoing Maintenance Hemodialysis.

Experimental Study of Subchronic Toxicity of Lanthanum Nitrate on Liver in Rats

The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats

Lanthanum chloride exerts therapeutic potential for chronic kidney disease by suppressing nanohydroxyapatite-induced mitophagy and mitochondria-mediated apoptosis

Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.

The Role of Iron-Based Phosphate Binder in the Treatment of Hyperphosphatemia